The trial is taking place at:
P

Palmetto Clinical Research | Summerville, SC

Veeva-enabled site

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

C

CinPhloro Pharma, LLC

Status and phase

Enrolling
Phase 2

Conditions

Irritable Bowel Syndrome With Diarrhea

Treatments

Drug: CIN-103
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT06153420
CIN-103-121

Details and patient eligibility

About

The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant diarrhea (IBS-D) in adult patients. The main questions it aims to answer are: To evaluate the efficacy of CIN-103 on symptoms of IBS-D when given to patients with IBS-D compared to a placebo. To evaluate the safety and tolerability of CIN-103 when given to patients with IBS-D compared to a placebo Participants will attend the following visits: Screening Period (1 Visit) Baseline Period (1 Visit) Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued participation. 12-Week Treatment Period (5 Visits) Study drug taken twice daily by mouth. Will complete daily diaries and other PROs as described in the protocol. Follow- Up Period (1 Visit) Researchers will compare CIN-103 Dose 1, CIN-103 Dose 2, and placebo, to evaluate the clinical response to multiple dose strengths of CIN-103 relative to placebo on abdominal pain and stool consistency along with safety and tolerability.

Enrollment

450 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Are adult male and female subjects ≥ 18 years of age;
  • Have a body mass index between 18 and 40 kg/m2, inclusive at Screening;

Meet Rome IV Criteria for IBS-D by subject self-report of recurrent abdominal pain that is associated with ≥ 2 of the following over the last ≥ 6 months, with frequency of at least 1 day per week over the last 3 months (on average) before enrollment:

  • Related to defecation;
  • Associated with a change in frequency of stool; and/or
  • Associated with a change in form (appearance of stool).
  • Based on Investigator interview of subject's symptoms over the last 3 months, have ≥ 25% of bowel movements (BMs) with Bristol Stool Scale (BSS) Type 6 or 7 (loose or watery stools) and < 25% of BMs with BSS Type 1 or 2 (lumpy or hard stools) per the Rome IV Criteria for IBS-D;
  • In the opinion of the Investigator, are on a stable diet for ≥ 4 weeks prior to Screening and are not planning to change lifestyle, exercise, and/or diet that may impact symptoms of IBS-D during study participation;
  • Have a fecal calprotectin ≤ 50 mcg/g at the Screening Visit or Visit 2; Note: A single normal test result is adequate for study eligibility. If subjects are rescreened within 6 months, there is no need for repeat fecal calprotectin sample collection and testing. However, subjects who fail screening due to an abnormal calprotectin level are not eligible for re-screening.
  • Have a serum tTG-IgA (tissue transglutaminase immunoglobulin A) ≤ 4.99 FLU (fluorescent light units) at the Screening Visit;

Have undergone a colonoscopy examination within the designated time interval prior to randomization, if they meet any of the following criteria. Note: A negative Cologuard® test result is an acceptable alternative to colonoscopy for subjects ≥ 45 years and at average risk for colon cancer.

  • Average risk, based on US Preventive Services Task Force Recommendation Statement for screening of colorectal cancer, with age ≥ 45 years (colonoscopy within 10 years or negative test results on Cologuard within 3 years);
  • Personal history of completely removed adenomatous colorectal polyps (colonoscopy within 5 years for polyps >1 cm, within 10 years for polyps <1 cm);
  • History of colorectal cancer or adenomatous polyps in a first-degree relative before age 60 (colonoscopy within 5 years); or
  • History of colorectal cancer or adenomatous polyps in ≥ 2 first-degree relatives at any age, or family history of hereditary colorectal cancer or polyposis (colonoscopy within 5 years).

Exclusion criteria

Have a diagnosis or suspected diagnosis of non-diarrhea predominant IBS (eg, IBS with a subtype of constipation, IBS with mixed or alternating bowel habits, un-subtyped IBS) or functional constipation by the Rome IV Criteria;

Have a history of or current inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis, indeterminate colitis), microscopic colitis, lymphocytic colitis, celiac disease, non-celiac gluten sensitivity and non-compliant on a gluten-free diet, untreated lactose intolerance, carcinoid syndrome, Lynch syndrome, or familial polyposis;

Note: Lactose intolerance and non-celiac gluten sensitivity will not exclude a subject from participation if the Investigator documents that the subject is compliant on a special diet (lactose-free diet or gluten-free diet, respectively) and/or for lactose intolerance is successfully treated with commercial lactase supplement(s).

  • Have a known family history of inflammatory bowel disease in at least 1 first-degree relative;
  • Have a known history of a pelvic floor disorder (unless successful treatment has been documented by a normal balloon expulsion test), refractory constipation not responsive to standard medical therapy, fecal impaction that required hospitalization, cathartic colon, and/or active proctological condition;
  • Have a history of or current non-IBS chronic condition(s) with ongoing symptoms associated with abdominal pain or GI discomfort (eg, gastroparesis, functional dyspepsia, uncontrolled gastroesophageal reflux disease, polycystic kidney disease, ovarian cysts, urological pain, or endometriosis);
  • Have a history of or current clinically significant arrhythmias as judged by the Investigator, including ventricular tachycardia, ventricular fibrillation, and Torsades de pointes. Subjects with any abnormal electrocardiogram (ECG) not considered clinically significant by the Investigator are not excluded;

Have current or a history of diverticulitis, heme positive stool, or unexplained GI bleeding within 3 months prior to Screening

Note: Surgically repaired diverticulitis > 3 months prior to Screening is permitted.

Have a history of surgical resection of the stomach, small, or large intestine;

Have had any major abdominal surgery within the 3 months prior to Screening;

Note: Permitted procedures are uncomplicated appendectomy, cholecystectomy, and resection of benign polyps within the 3 months prior to Screening. Subjects who had an appendectomy that was associated with any related complications or sequelae are eligible if the procedure was performed at least 6 months prior to Screening.

  • Have a history of intestinal obstruction, stricture, toxic megacolon, solitary rectal ulcer syndrome, GI perforation, intra-abdominal or pelvic adhesions, ischemic colitis, radiation proctitis, enteritis, colitis, or impaired intestinal circulation (eg, aortoiliac disease);
  • Are currently undergoing or planning to initiate treatment with weight loss medication during study participation or prior weight loss surgery (eg, gastric bypass surgery, gastric banding);
  • Have a planned invasive elective surgery during the period of anticipated study participation from the time of informed consent through the last study visit;

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

450 participants in 3 patient groups, including a placebo group

CIN-103 BID Dose 1
Experimental group
Description:
CIN-103 Dose 1, administered as 2 x CIN-103 capsules and 2 x matching placebo per dose. Two doses per day.
Treatment:
Drug: CIN-103
CIN-103 BID Dose 2
Experimental group
Description:
CIN-103 Dose 2, administered as 4 x CIN-103 capsules per dose. Two doses per day.
Treatment:
Drug: CIN-103
Placebo for CIN-103 BID
Placebo Comparator group
Description:
Placebo for CIN-103, administered as 4 x matching placebo capsules per dose. Two doses per day.
Treatment:
Drug: Placebo

Trial contacts and locations

47

Loading...

Central trial contact

Lauren Brown

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems